ADAMO ROBOT

Adamo Robot SL (ADAMO) was born in 2021 and has created the Adamo Robot robotic system: a device that integrates state-of-the-art components (UR arm and FLIR thermal camera) and uses a jet of pressurized heated/cooled air for the treatment of all types of musculoskeletal disorders. The company is finishing the process of qualifying Adamo Robot as a Medical Device during 2024. With a first version of the robot on the market, ADAMO is committed to R&D and is about to begin development of the new version of its current product, which will simplify manufacturing and improve operating margins. The company has recently signed a long-term collaboration agreement with CIBIR (The Center for Biomedical Research of La Rioja/Spain).

ADNTRO GENETICS

ADNTRO Genetics is at the forefront of genetic testing and bioinformatics, offering innovative solutions through direct-to-consumer services, business-to-business partnerships, and cutting-edge research in the development of Polygenic Risk Scores (PRS) for complex diseases. Our comprehensive approach harnesses the latest in genetic science to provide valuable insights into health, ancestry, and personal well-being.

ALLINKY BIOPHARMA

ALLINKY BIOPHARMA is a Spanish drug discovery and development company founded in 2009. Allinky has developed its own proprietary technology platform to identify allosteric sites in protein targets, and to thereafter develop allosteric inhibitors (New Chemical Entities, NCE) with unparalleled therapeutic properties. The design of each molecule is unique, and it requires challenging R&D activity, both at the computational and chemical levels. Allinky is currently advancing drug development programs focused on two families of innovative proprietary allosteric inhibitors: AIK3 and AIK4, addressing the molecular causes of inflammation and cancer, respectively. Within the AIK3 inflammation program, we are focused on bringing our most advanced candidate, a potent oral inhibitor of IL-1β production, into Phase IIa clinical trials. To this end, our roadmap includes conducting the latest regulatory toxicology study in dogs, applying for the CTA to the EMA and carrying out Phase I and Phase IIa PoC clinical trials.

AQUILON CyL

Aquilon develops innovative biological agents (vaccines, probiotics and optimized diagnostics) to reduce or eliminate antibiotic usage in key diseases affecting animal productivity, in line with OneHealth and EU priorities.

BATEA ONCOLOGY

Batea Oncology is a biotech company developing innovative solutions for the treatment of aggressive cancers with low survival. In particular, we have developed GlioHook, a class III medical device for the treatment of glioblastoma (GB) patients. In animal Glioblastoma models, GlioHook concentrates tumor cells remaining at the tumor resection margins after surgery, the main responsible of tumor relapse, changing the disease from an infiltrative to a focalized one. We have compelling in vitro and vivo evidence showing that GlioHook has a positive effect on survival when combined with radiotherapy, the standard of care for GB patients. Our next objective is to perform a Phase I clinical trial starting in 2Q 2025 to test safety and obtain preliminary efficacy data.

DIVE MEDICAL

DIVE Medical S.L, is a medical technology company that offers a technological platform for the diagnosis of pathologies through vision. DIVE (Devices for an Integral Visual Examination) is a proprietary technology based on eye tracking and artificial intelligence. The company already has the first version of its medical device, with which visual tests are performed automatically in a few minutes, with a simple and intuitive interface and without the need for intervention by a specialist, who only has to interpret the data. The device encompasses the company's first two products, which focus on screening and complete examination of visual function objectively, quickly and accurately, even in non-verbal patients, such as infants, young children, and people with cognitive impairment: DIVE AI Vision Screening: To automatically identify children with visual problems who should be referred to a specialist & DIVE Vision Exam: For vision diagnosis and monitoring by specialists (ophthalmologists and optometrists).

DOCTOMATIC

Doctomatic is a remote patient monitoring medical software tool which transmits the data provided by non-invasive medical devices via a mobile app to a medical platform whereby medical professionals analyze and evaluate the information of their patients. Doctomatic is a remote patient monitoring tool working towards removing the burden of over 5 Billion chronic patients globally. Doctomatic empowers patients by allowing their doctors to monitor their health data daily and assist them in predicting the deterioration of their conditions.

FLOMICS BIOTECH

Flomics Biotech, established in 2018 in Barcelona, stands at the forefront of cancer diagnostics with a novel and groundbreaking liquid biopsy solution for multicancer early detection. Our innovative blood-based test transcends traditional methods by utilizing a unique combination of cell-free RNA sequencing and advanced bioinformatics, including machine learning and AI, to identify robust cancer signatures from a single blood sample. This allows for the non-invasive screening of multiple cancer types, offering a significant leap in early cancer detection.

GATE2BRAIN

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier using a radically innovative peptide-based patented technology platform. G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

INHIBITEC ANTICUERPOS

Inhibitec, a pioneering biotechnology startup, that emerged as a spin off company from University of Cantabria, (group led by Dr. Jesus Merino, MD, PhD), and the Spanish National Research Council (CSIC), (group led by Dr. Ramon Merino, MD, PhD). Discovery of BAMBI as a pivotal molecule governing the differentiation of CD4 lymphocytes and development of B101.37, a murine monoclonal antibody (mAb) designed to selectively inhibit BAMBI, showing remarkable therapeutic potential for autoimmune /chronic inflammatory diseases like psoriasis, Psoriatic Arthritis (PsA), and rheumatoid arthritis.

INNOUP FARMA

Clinical-stage drug development company. Spin-off Universidad de Navarra. Strong IP portfolio. Patented nanotechnology platform. 2 clinical trials on-going.

INTEGRA THERAPEUTICS

Limitations of gene therapy technologies hinder their broader application. Integra Therapeutics’ FiCAT technology addresses this, enabling large-DNA integration with unprecedented precision. With over €9M in VC and non-dilutive funding, plus notable pharma collabs, we're geared to hit significant milestones during our Series A. As we initiate preclinical development, we are focusing on liver paediatric rare diseases, where FiCAT is poised to provide the first curative treatment. Our team, led by acclaimed experts and strategic investors, is ready to lead this revolution. At Integra Therapeutics, we're not just developing gene therapies – we're writing the future of gene therapy with FiCAT.

GENBIOMA APLICACIONES

Genbioma is a R&D biotech company for healthcare innovation commercially oriented to the international market of a new generation of Probiotics & Postbiotics. Our mission is simple: improve peoples´ health through microbiome products. By targeting the gut microbiota with specific strains we can regulate glucose and lipid metabolism to improve health (diabetes, obesity, hypercholesterolemia). Genbioma focuses on scientific innovation for preventing and combating metabolic diseases. Several research showed microbiome has a significant impact on improving health. By targeting gut microbiota with specific strains, we can regulate glucose and lipid metabolism. Genbioma has created a platform to develop natural Microbiome-based solutions to improve metabolism and health. Our technology uses the latest advances in Microbiome Science to screen specific bacterial strains effective on glucose and lipid metabolism. We use a novel in vivo model (C. elegans) and the latest metagenomic and metabolomic advances to understand the mechanism of action. Thanks to this novel screening platform, we have gathered a proprietary collection of microorganisms that can modulate key metabolic biomarkers by modifying the gut microbiota.

MIKROBIOMIK HEALTHCARE

Mikrobiomik is a bio-pharmaceutical company established in 2018 and headquartered in Derio, Bizkaia. The company specializes in researching, developing, and manufacturing medicines based on the human microbiome. Its flagship product, MBK-01, utilizes FSPIM® (Full Spectrum and Purified Intestinal Microbiota) technology, delivered in the form of lyophilized oral capsules aimed at treating Clostridioides difficile infections. Mikrobiomik also has various other indications in different stages of development.

MIRAMOON PHARMA

Established as a spin-off of the University of the Basque Country and Biogipuzkoa Health Research Institute, Miramoon Pharma SL is dedicated to developing innovative medications. Miramoon Pharma's approach involves a dual mechanism of action in their compounds: normalizing intracellular calcium levels in photoreceptors by modulating RyR channels and acting as scavengers of ROS free radicals. This approach holds promise for providing treatments for musculoskeletal, cardiac and nervous system disorders). Miramoon Pharma's Intellectual Property portfolio is solid, with patents granted protecting a large family of compounds across major markets since 2016, and additional filings targeting ocular diseases. Miramoon Pharma SL aims to make tangible advancements in treating Neurodegenerative and Rare Diseases, emphasizing a commitment to patient welfare and scientific integrity.

NANODECAL

Nanodecal is a spin-off company from the Health Research Institute of the Balearic Islands that is developing rapid tests for respiratory superbugs.

NUCAPS

NUCAPS is an international biotechnology company that develops and produces a new kind of functional ingredients: Protein microencapsulated bioactives and probiotics with improved functionalities in terms of nutrition and costs to get a real impact on human health. We are part of the new society and a positive social impact. NUCAPS improves people's Nutrition & Health as we help to produce better food, supplements and drugs by making nutritional ingredients stable, easy to absorb, healthy and natural.

ONENA MEDICINES

Onena Medicines is a Stanford Univeristy spinout biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat advanced cancers and other indications. Onena’s drugs neutralize novel growth factors called Dual SMAD Inhibiting Proteins, resulting in local environmental signaling that instructs diseased cells to either die or mature. Our pipeline is fueled by an artifical intelligence driven platform that combines cutting edge technologies like adversarial neural netowrks (ANN) based antibody optimization with bespoke DSIP wet lab assays to accelerate drug discovery.

ONIRIA THERAPEUTICS

Oniria Therapeutics, S.L. is a biopharmaceutical company focused on the field of precision oncology. It develops first-in-class targeted therapies to modulate and eliminate dormant tumor cells (slow cycling cells) as a novel targeted strategy to overcome their persistence and prevent patients’ progression to advanced stages of cancer. Oniria is a spin-off of the Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA) created on December 23, 2021, which was created as an instrument to attract investment, valorize the technology developed during more than 15 years and had been licensed exclusively to Oniria, and bring it to patients. Oniria Therapeutics’ entrepreneurial team is multidisciplinary and consists of 6 professionals: Dr Héctor García Palmer, Esther Riambau, Dr Xavier Barril, Dr Isabel Puig, Dr Carlos Galdeano and Dr Josep Tabernero.

PEACHES BIOTECH

We have developed a disruptive model based on selective secretomes for obtaining new drugs. We investigate a generation of advanced biological drugs (secretome) through an innovative, highly efficient and safe cell co-culture platform.

ZECARDIO THERAPEUTICS

ZeCardio Therapeutics (ZeCardioTx) is a biotech company aiming to revolutionize the discovery of new cardiovascular drugs impacting the lives of millions of patients suffering from acute myocardial infarction, genetic heart diseases and heart failure caused by anti-tumoral cardiotoxic side-effects. These diseases represent highly unmet medical needs and huge market opportunities.